J Morgan Freiman1, Wei Huang1, Laura F White2, Elvin H Geng3, Christopher B Hurt4, Lynn E Taylor5, E Turner Overton6, Edward R Cachay7, Mari M Kitahata8, Richard D Moore9, Benigno Rodriguez10, Kenneth H Mayer11, Benjamin P Linas12. 1. HIV Epidemiology and Outcomes Research Unit, Section of Infectious Diseases, Boston Medical Center. 2. Departments of Biostatistics. 3. School of Medicine, University of California, San Francisco. 4. Institute for Global Health and Infectious Diseases, University of North Carolina at Chapel Hill. 5. Department of Medicine, Brown University, Providence, Rhode Island. 6. Division of Infectious Diseases, University of Alabama at Birmingham School of Medicine. 7. Department of Medicine, University of California, San Diego. 8. Division of Allergy and Infectious Diseases, Department of Medicine, University of Washington, Seattle. 9. Division of Infectious Diseases, Johns Hopkins University, Baltimore, Maryland. 10. Division of Infectious Diseases and HIV Medicine, Case Western Reserve University, Cleveland, Ohio. 11. Fenway Institute, Fenway Health, Boston, Massachusetts. 12. HIV Epidemiology and Outcomes Research Unit, Section of Infectious Diseases, Boston Medical Center Epidemiology, Boston University School of Public Health, Massachusetts.
Abstract
BACKGROUND: Human immunodeficiency virus (HIV)-infected, hepatitis C virus (HCV)-uninfected patients are at risk for incident HCV infection, but little is known about screening practices for incident HCV among HIV-infected individuals in HIV primary care clinics. METHODS: We used data from the Center for AIDS Research Network of Integrated Clinical Systems (CNICS) to investigate historical trends in screening for incident HCV infection among HIV-infected patients who were HCV-uninfected at enrollment in care. We used descriptive measures and Poisson regression to identify factors associated with screening for HCV infection (using HCV antibody or RNA), performed temporal analyses to assess changes in screening over time, and investigated the frequency with which elevated alanine aminotransferase (ALT) levels were followed by diagnostic HCV testing. RESULTS: Among 17 090 patients registered at CNICS sites between 2000 and 2011, 14 534 (85%) received HCV antibody screening within 3 months of enrolling in care, and 9077 met all of the inclusion criteria. Only 55.6% ever received additional HCV screening. HCV screening increased over time, but not uniformly at all sites. Only 26.7% of first-time ALT elevations to >100 IU/L were followed up within 12 months by HCV antibody or RNA testing. CONCLUSIONS: Although most HIV-infected patients were screened for prevalent HCV infection at enrollment in care, only half who were HCV uninfected were screened again. Screening varied between sites, even when controlling for demographics and risk behaviors. Patients with new ALT elevations to >100 IU/L were seldom assessed for incident HCV infection. Guidelines are needed to help HIV providers know whom to screen, how frequently to screen, and which screening test to use.
BACKGROUND: Human immunodeficiency virus (HIV)-infected, hepatitis C virus (HCV)-uninfected patients are at risk for incident HCV infection, but little is known about screening practices for incident HCV among HIV-infected individuals in HIV primary care clinics. METHODS: We used data from the Center for AIDS Research Network of Integrated Clinical Systems (CNICS) to investigate historical trends in screening for incident HCV infection among HIV-infected patients who were HCV-uninfected at enrollment in care. We used descriptive measures and Poisson regression to identify factors associated with screening for HCV infection (using HCV antibody or RNA), performed temporal analyses to assess changes in screening over time, and investigated the frequency with which elevated alanine aminotransferase (ALT) levels were followed by diagnostic HCV testing. RESULTS: Among 17 090 patients registered at CNICS sites between 2000 and 2011, 14 534 (85%) received HCV antibody screening within 3 months of enrolling in care, and 9077 met all of the inclusion criteria. Only 55.6% ever received additional HCV screening. HCV screening increased over time, but not uniformly at all sites. Only 26.7% of first-time ALT elevations to >100 IU/L were followed up within 12 months by HCV antibody or RNA testing. CONCLUSIONS: Although most HIV-infected patients were screened for prevalent HCV infection at enrollment in care, only half who were HCV uninfected were screened again. Screening varied between sites, even when controlling for demographics and risk behaviors. Patients with new ALT elevations to >100 IU/L were seldom assessed for incident HCV infection. Guidelines are needed to help HIV providers know whom to screen, how frequently to screen, and which screening test to use.
Authors: L E Taylor; A K DeLong; M A Maynard; S Chapman; P Gholam; J T Blackard; J Rich; K H Mayer Journal: AIDS Patient Care STDS Date: 2011-08-22 Impact factor: 5.078
Authors: Carrie McAdam-Marx; Lisa J McGarry; Christopher A Hane; Joseph Biskupiak; Baris Deniz; Diana I Brixner Journal: J Manag Care Pharm Date: 2011-09
Authors: J Ghosn; C Deveau; C Goujard; I Garrigue; N Saïchi; J Galimand; Z Nagy; C Rouzioux; L Meyer; M-L Chaix Journal: Sex Transm Infect Date: 2006-08-21 Impact factor: 3.519
Authors: Mark Danta; David Brown; Sanjay Bhagani; Oliver G Pybus; Caroline A Sabin; Mark Nelson; Martin Fisher; Anne M Johnson; Geoffrey M Dusheiko Journal: AIDS Date: 2007-05-11 Impact factor: 4.177
Authors: Richard S Garfein; Elizabeth T Golub; Alan E Greenberg; Holly Hagan; Debra L Hanson; Sharon M Hudson; Farzana Kapadia; Mary H Latka; Lawrence J Ouellet; David W Purcell; Steffanie A Strathdee; Hanne Thiede Journal: AIDS Date: 2007-09-12 Impact factor: 4.177
Authors: Jannie J van der Helm; Maria Prins; Julia del Amo; Heiner C Bucher; Geneviève Chêne; Maria Dorrucci; John Gill; Osamah Hamouda; Mette Sannes; Kholoud Porter; Ronald B Geskus Journal: AIDS Date: 2011-05-15 Impact factor: 4.177
Authors: Deepa G Gamage; Tim R H Read; Catriona S Bradshaw; Jane S Hocking; Kerry Howley; Marcus Y Chen; Christopher K Fairley Journal: BMC Infect Dis Date: 2011-02-03 Impact factor: 3.090
Authors: Taraz Samandari; Ellen Tedaldi; Carl Armon; Rachel Hart; Joan S Chmiel; John T Brooks; Kate Buchacz Journal: Open Forum Infect Dis Date: 2017-06-10 Impact factor: 3.835
Authors: Jun Li; Carl Armon; Frank J Palella; Ellen Tedaldi; Richard M Novak; Jack Fuhrer; Gina Simoncini; Kimberly Carlson; Kate Buchacz Journal: Open Forum Infect Dis Date: 2021-04-17 Impact factor: 3.835
Authors: Yun-Chi Chen; Kjell J Wiberg; Yu-Hsiang Hsieh; Arun Bansal; Philipe Bolzan; Janelle A Guy; Erastus N Maina; Andrea L Cox; Chloe L Thio Journal: Open Forum Infect Dis Date: 2016-06-29 Impact factor: 3.835
Authors: Edward R Cachay; Lucas Hill; Francesca Torriani; Craig Ballard; David Grelotti; Abigail Aquino; W Christopher Mathews Journal: Open Forum Infect Dis Date: 2018-07-31 Impact factor: 3.835
Authors: Antoine Chaillon; Xiaoying Sun; Edward R Cachay; David Looney; David Wyles; Richard S Garfein; Thomas C S Martin; Sonia Jain; Sanjay R Mehta; Davey M Smith; Susan J Little; Natasha K Martin Journal: Open Forum Infect Dis Date: 2019-04-03 Impact factor: 3.835
Authors: Edward R Cachay; Lucas Hill; David Wyles; Bradford Colwell; Craig Ballard; Francesca Torriani; William C Mathews Journal: PLoS One Date: 2014-07-18 Impact factor: 3.240
Authors: Alysse G Wurcel; Daniel D Chen; Rosemary E Fitzpatrick; Paula E Grasberger; Caleb H Kirshner; Jordan E Anderson; Kenneth K H Chui; Tamsin A Knox Journal: Open Forum Infect Dis Date: 2016-02-12 Impact factor: 3.835